Telehealth Narcolepsy Prescribing: What Psychiatric NPs Can Do in Florida

You’ve built your practice around helping patients manage complex psychiatric conditions. Now you’re considering whether you can — or should — treat narcolepsy via telehealth. Maybe a patient mentioned their debilitating daytime sleepiness, or you’re exploring new revenue streams in an underserved specialty.

Here’s the reality: narcolepsy is one of the most underdiagnosed and undertreated neurological conditions in America, affecting roughly 160,000 people (about 1 in 2,000). Most of those patients can’t access specialized care. Sleep medicine specialists are scarce, especially in rural areas. And while narcolepsy isn’t technically a psychiatric disorder, its primary treatments — stimulants and wakefulness-promoting agents — fall squarely within the prescriptive authority of psychiatrists and many PMHNPs.

The question isn’t whether providers can treat narcolepsy via telehealth. It’s whether you can, given your credentials and state licensing — and whether it makes financial and clinical sense for your practice.

Let’s break down exactly what psychiatrists and PMHNPs can do, which states allow what, and how telehealth economics actually work for this specialty niche.

What Psychiatrists Can Do: Full Authority, With Compliance Strings Attached

If you’re a board-certified psychiatrist (MD or DO), your scope is straightforward: you can diagnose and manage narcolepsy in any state where you’re licensed, including via telehealth, as long as you follow controlled substance regulations.

Your Clinical Authority

Psychiatrists can prescribe the full range of narcolepsy medications:

• Schedule II stimulants (amphetamine salts like Adderall, methylphenidate like Ritalin, dextroamphetamine)
• Schedule IV wakefulness agents (modafinil/Provigil, armodafinil/Nuvigil)
• Newer agents (solriamfetol/Sunosi, pitolisant/Wakix)
• Sodium oxybate (Xyrem/Xywav — a Schedule III controlled substance with a REMS program for cataplexy management)
• Off-label adjuncts (SSRIs or SNRIs for cataplexy, sedatives for disrupted nighttime sleep)

Your training in psychopharmacology and experience managing stimulants for ADHD translates directly to narcolepsy care. You already know how to titrate doses, monitor for abuse potential, check blood pressure and heart rate, and coordinate with specialists when needed.

The Telehealth Advantage (and Current Rules)

As of early 2026, the DEA’s pandemic-era flexibilities remain in effect through at least the end of 2025, extended by recent federal action. This means you can initiate Schedule II stimulant prescriptions via telehealth without an initial in-person exam, provided you conduct a proper video evaluation and document appropriately.

Here’s what that means practically:

• A new narcolepsy patient in California can book a video visit with you, present their sleep study results (polysomnogram with MSLT showing classic narcolepsy findings), and you can start them on Adderall or modafinil that same day via e-prescription
• You must be licensed in the patient’s state and registered with the DEA for that state
• You must check the state’s prescription drug monitoring program (PDMP) before prescribing — mandatory in nearly all states
• You use DEA-compliant electronic prescribing for controlled substances (EPCS)

What happens after 2025? The DEA has been debating permanent telehealth rules for controlled substances. The most likely scenario is either an extension of current flexibilities or a requirement for an in-person exam within 30 days of initiating Schedule II medications. Platforms like ours are preparing for both scenarios — either maintaining fully virtual workflows or coordinating one-time in-person evaluations through local provider networks.

State-Specific Wrinkles for Psychiatrists

Even with your MD/DO credentials, a few states impose unique restrictions on telehealth controlled substance prescribing:

Florida is the big outlier. State law (Fla. Stat. 456.47) prohibits prescribing Schedule II controlled substances via telehealth unless it’s for psychiatric treatment, inpatient/hospital care, hospice, or chronic pain management. Since narcolepsy is technically a neurological disorder (not psychiatric), a strict interpretation means you cannot prescribe Adderall for narcolepsy purely via telehealth in Florida without at least one in-person exam.

The workaround: Many Florida tele-psychiatrists prescribe modafinil (Schedule IV, which is explicitly allowed via telehealth under Florida’s 2022 SB 312 law) as first-line therapy. If a patient has comorbid ADHD or depression, you might argue the stimulant falls under ‘psychiatric treatment.’ It’s a gray area — consult legal counsel if you’re practicing in Florida.

Texas has no physician-specific telehealth restrictions on controlled substances, but the state requires a valid practitioner-patient relationship established through appropriate telemedicine standards (video visit, sufficient examination for the condition). You’re good to go as long as you document thoroughly.

All other states generally align with federal rules: video-based telehealth visits that meet the standard of care can support controlled substance prescribing. Audio-only phone calls typically do not qualify for initiating stimulant therapy.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What PMHNPs Can Do: It Depends Entirely on Your State

If you’re a Psychiatric-Mental Health Nurse Practitioner, your ability to prescribe narcolepsy medications via telehealth varies wildly based on state scope-of-practice laws. This is where things get complicated — and where many PMHNPs underestimate or overestimate their authority.

The Core Question: Can You Prescribe Schedule II Stimulants Independently?

Narcolepsy’s first-line treatments are Schedule II controlled substances. Whether you can prescribe them depends on:

1. Your state’s NP independence laws (full practice, reduced practice, or restricted practice)
2. Specific controlled substance prescribing limits in your state
3. Whether you’ve met experience thresholds (where applicable)

Let’s break down the key states:

Full or Near-Full Practice States (After Experience Requirements)

California: As of 2026, California NPs can achieve full independence through AB 890’s transition pathway. If you’ve completed 4,600 hours (roughly 3 years) as a ‘103 NP’ in a collaborative practice setting, you can apply for ‘104 NP’ status — fully independent practice within your population focus. A 104-certified PMHNP can prescribe Schedule II stimulants for narcolepsy without any physician involvement.

Until you reach 104 status, you need physician-approved standardized procedures for Schedule II prescribing. Your collaborating MD must sign off on specific protocols covering stimulant use, and historically California required additional pharmacology coursework for Schedule II authority. Doable, but bureaucratic.

New York: After 3,600 hours of practice (about 2 years), New York PMHNPs no longer need any collaborative agreement or physician oversight. You practice independently and can prescribe Schedule II–V controlled substances just like a psychiatrist. This became permanent law in 2022, so experienced NY PMHNPs have full narcolepsy prescribing authority.

Before hitting 3,600 hours, you need a written collaborative practice agreement with a physician that covers stimulant prescribing. The physician doesn’t co-sign every prescription, but they’re listed in your protocol and available for consultation.

Illinois: Illinois grants Full Practice Authority (FPA) to NPs after 4,000 hours of collaborative practice plus 250 hours of continuing education in pharmacology. Once you have FPA, you can prescribe Schedule II–V independently.

Important Illinois caveat: The law requires FPA NPs to maintain a physician ‘consultation relationship’ when prescribing Schedule II narcotics (opioids) long-term, and a physician consult after 120 days of benzodiazepine prescribing. Stimulants are not included in these restrictions. You can prescribe Adderall or modafinil for narcolepsy without mandated physician involvement once you have FPA status.

Restricted Practice States (You’ll Need a Collaborating Physician)

Texas: Texas is one of the most restrictive states for NP practice. You must have a Prescriptive Authority Agreement (PAA) with a supervising physician, and Texas law prohibits NPs from prescribing Schedule II controlled substances for outpatient care — with rare exceptions for hospital inpatients (≥24 hours admitted) or hospice patients.

Translation: A Texas PMHNP cannot prescribe Adderall or Ritalin for a narcolepsy patient in routine telehealth practice. Your collaborating physician would have to write those prescriptions. You can prescribe Schedule IV medications like modafinil (up to a 90-day supply), but managing narcolepsy patients who need stimulants requires physician partnership.

This is a dealbreaker for independent NP narcolepsy practice in Texas. If you’re licensed there and want to treat narcolepsy via telehealth, you’ll need a Texas-licensed psychiatrist or other MD willing to prescribe the Schedule IIs while you handle everything else.

Florida: Florida requires PMHNPs to practice under a physician collaborative agreement (psychiatric NPs were explicitly excluded from Florida’s 2020 autonomous practice pathway). You can prescribe Schedule II stimulants, but Florida law limits APRN Schedule II prescriptions to a 7-day supply maximum — unless you’re a state-certified ‘psychiatric nurse’ prescribing for psychiatric conditions.

The problem: Narcolepsy isn’t a psychiatric disorder, so technically even a Florida PMHNP is bound by the 7-day limit. That means writing or e-prescribing a new Adderall script every week, which is administratively insane for ongoing management.

The workaround: Use modafinil or armodafinil (Schedule IV, no quantity limits) as first-line therapy. Many Florida PMHNPs also collaborate closely with their supervising psychiatrist to have the physician write 30-day stimulant prescriptions when needed.

Additionally, Florida’s telehealth law restricts Schedule II prescribing via telemedicine for non-psychiatric conditions. Between the 7-day limit and the telehealth ban, Florida is tough terrain for PMHNP narcolepsy care. It’s doable with the right physician partnership and by preferring non-Schedule II wakefulness agents.

Pennsylvania: Pennsylvania requires all NPs (CRNPs) to maintain a written collaborative agreement with a physician. You can prescribe Schedule II controlled substances, but state regulations limit you to a 30-day supply (and you must notify your collaborating physician within 24 hours). Schedule III–IV can be prescribed for up to 90 days.

For narcolepsy management, this means monthly follow-ups to write new stimulant prescriptions — which actually aligns with best practices for controlled substance management anyway. Pennsylvania NPs can absolutely treat narcolepsy via telehealth; you just can’t do it independently without a physician collaborator on record.

Key Takeaway for PMHNPs

• Experienced NPs in CA, NY, IL: You can manage narcolepsy as independently as a psychiatrist (after meeting your state’s hour thresholds and requirements)
• NPs in TX, FL, PA: You need a collaborating physician, and in Texas specifically, that physician must write Schedule II prescriptions
• All NPs: Check your state’s PDMP requirements (mandatory in nearly all states), ensure your e-prescribing system is EPCS-compliant, and verify your DEA registration covers the state where your patient resides

The Clinical Workflow: What Narcolepsy Management Actually Looks Like

Whether you’re an MD or NP, managing narcolepsy via telehealth follows a predictable pattern that’s both clinically rewarding and economically viable.

Initial Evaluation (30–45 minutes)

Most narcolepsy patients come to you with a diagnosis already confirmed by sleep study (polysomnography showing reduced sleep latency, followed by MSLT showing multiple sleep-onset REM periods). If they don’t have documentation, you refer them to a sleep specialist or local sleep lab for testing — narcolepsy diagnosis cannot be made on symptoms alone.

Your intake visit covers:

• Reviewing sleep study results and diagnosis type (narcolepsy type 1 with cataplexy, type 2 without cataplexy)
• Assessing symptom severity (Epworth Sleepiness Scale, frequency of sleep attacks, impact on work/driving)
• Screening for comorbid conditions (depression, anxiety, ADHD — common in narcolepsy patients)
• Ruling out other causes of excessive daytime sleepiness (sleep apnea, medication side effects, shift work disorder)
• Discussing medication options, side effects, and treatment goals
• Obtaining informed consent for controlled substance prescribing
• Checking state PDMP for any prior controlled substance history

You document everything thoroughly (more on this below), choose a starting medication (often modafinil 200mg daily or methylphenidate 10mg twice daily), e-prescribe it, and schedule a 2–3 week follow-up.

Ongoing Medication Management (15–20 minutes monthly or quarterly)

Once stable, narcolepsy patients need regular check-ins:

• Symptom review: Are they still having sleep attacks? How’s their alertness during work/school?
• Side effect monitoring: Blood pressure, heart rate, weight, appetite, mood, sleep quality at night
• Medication adjustments: Dose titration, switching agents if needed, adding adjunct medications (e.g., SSRI for cataplexy)
• Refill prescriptions: Monthly for Schedule II stimulants (no refills allowed federally), quarterly for Schedule IV meds
• PDMP checks: Required at each controlled substance prescription in most states

These visits are brief and focused — exactly the kind of efficient medication management that works well in telehealth. You’re billing for a 99213 or 99214 E/M code (evaluation and management), which reimburses around $80–$130 depending on payer and complexity.

Coordination with Other Providers

Many narcolepsy patients also see:

• A sleep specialist (for periodic re-evaluation or if symptoms aren’t controlled)
• A primary care physician (for routine health maintenance, managing blood pressure if stimulants raise it)
• A psychologist or therapist (for adjustment to chronic illness, workplace/school issues, stigma)

You’ll document any care coordination in your notes. Some payers reimburse care coordination separately (using collaborative care codes), though it’s more common to just bill the E/M visit.

The Economics: What Does Narcolepsy Medication Management Pay?

Let’s talk money. Many providers hesitate to treat niche conditions because they assume low reimbursement or high administrative burden. Here’s the actual math for narcolepsy care.

Reimbursement Per Visit

• Initial evaluation (30–45 min): Bill 99204 or 99205 (new patient office visit). Medicare allowable: $165–$210. Private insurance: $200–$280.
• Follow-up medication check (15–20 min): Bill 99213 or 99214 (established patient). Medicare allowable: $80–$130. Private insurance: $110–$160.

If you see a narcolepsy patient monthly during titration (first 3 months), then quarterly once stable, that’s roughly:

• Year 1: 1 initial visit + 12 follow-ups = ~$1,400–$2,000 in reimbursement per patient per year
• Year 2+: 4 quarterly visits = ~$450–$600/year per patient

That’s comparable to managing a patient with depression or ADHD on medication — and narcolepsy patients tend to be extremely adherent because their symptoms are so debilitating without treatment.

Telehealth Parity and Medicare

Most states now mandate telehealth payment parity, meaning insurers must reimburse telehealth visits at the same rate as in-person. California, New York, Illinois, Pennsylvania, and many others have permanent parity laws.

Medicare (relevant for disabled narcolepsy patients under 65) currently reimburses tele-mental health at full rates through at least 2024, with likely extensions. The main wrinkle: Nurse practitioners are reimbursed at 85% of the physician fee schedule when billing under their own NPI. So if a psychiatrist gets $100 for a visit, a PMHNP gets $85 for the same service under Medicare.

Private insurers typically pay NPs and MDs equally in network, though there’s documented evidence that mental health providers overall receive about 22% lower reimbursement than other medical specialists — a parity enforcement issue that’s driving many psychiatrists to opt out of insurance panels.

The Self-Pay Alternative

Many narcolepsy patients are young, employed, and desperate for specialized care. If insurance reimbursement is too low or prior authorization too burdensome, cash-pay is viable:

• Initial consult: $250–$400
• Monthly follow-ups: $100–$150
• Quarterly follow-ups: $75–$125

Patients often prefer this over months-long waits to see a sleep specialist (average wait time for sleep medicine appointments in many areas: 3–6 months).

The Prior Authorization Tax

Here’s the biggest hidden cost: medication prior authorizations. Newer narcolepsy drugs (Sunosi, Wakix) and even generic modafinil often require PA, especially if insurers want to see proof of a confirmed diagnosis or evidence of failed cheaper alternatives.

Filling out a PA form takes 20–40 minutes of your time or your staff’s time. Multiply that by 10–20 patients, and you’re spending hours per week on unpaid paperwork.

How Klarity helps: Our platform handles PA submissions through our administrative team. You document the clinical rationale; we manage the insurance back-and-forth. That alone can save you 5–10 hours a month on narcolepsy patients.

Patient Acquisition: Why Traditional Marketing Is a Money Pit (And What Works Instead)

Let’s address the elephant in the room: how do you actually get narcolepsy patients to find you?

Many providers assume they’ll rank on Google for ‘narcolepsy treatment near me’ or that a Psychology Today listing will generate leads. Here’s the reality of DIY patient acquisition:

The True Cost of Acquiring Psychiatric Patients

• SEO (Search Engine Optimization): Takes 6–12 months of consistent content creation, technical optimization, and backlink building before you rank well enough to generate meaningful traffic. Cost: $2,000–$5,000/month for a competent agency. Most solo providers don’t have the expertise or patience.

• Google Ads (PPC): Mental health keywords are expensive. ‘Psychiatrist near me’ costs $15–$40 per click. ‘Narcolepsy treatment’ might be cheaper ($8–$15/click) but lower volume. Conversion rate from click to booked appointment: 3–8% if you’re lucky. Realistic cost per booked patient: $200–$400+. And that’s before factoring in no-shows (20–30% of cold leads from PPC).

• Directory Listings (Psychology Today, Zocdoc): Psychology Today charges $30–$40/month for a basic listing where you compete with hundreds of other providers on the same search results page. Zocdoc charges per booking ($35–$100+ depending on market and specialty) plus monthly subscription fees. Total monthly cost for meaningful lead flow: $300–$800+.

Add it all up: To reliably generate 10–20 new patient leads per month through DIY marketing, you’re spending $3,000–$5,000/month minimum — and that’s assuming you have the expertise to run effective campaigns. Most providers waste money on failed ads, poor SEO, and directories that generate zero qualified leads.

How Platforms Like Klarity Change the Economics

Instead of paying upfront for uncertain marketing results, you pay only when a qualified patient books an appointment. Here’s the model:

• No monthly retainers or ad spend: Zero upfront marketing investment
• Pay per booked appointment: A standard listing fee per new patient lead (similar to Zocdoc’s per-booking model, but patients are already matched to your specialty and availability)
• Pre-qualified patients: We handle initial intake, insurance verification, and symptom screening — you only see patients who actually need narcolepsy medication management
• No wasted clicks: Unlike Google Ads where 90% of clicks don’t convert, every patient we send you has already expressed intent to book

The economic logic is simple: Instead of gambling $3,000–$5,000/month on marketing channels that might generate patients, you pay a known fee per patient you actually see. That’s guaranteed ROI.

Built-in telehealth infrastructure is the other piece: You don’t need to pay for a separate telehealth platform ($50–$200/month for HIPAA-compliant video), an EPCS-enabled e-prescribing system ($50–$100/month), or a scheduling system. It’s all included. Your only variable cost is the per-patient fee — which you immediately recoup with the first visit reimbursement.

For Established Providers: Why This Still Makes Sense

Maybe you already have a patient panel and good Google ranking. You’re thinking, ‘Why would I pay per patient when I can market myself?’

Two reasons:

1. Specialty patients are harder to find organically. Your existing SEO and referral network brings you depression, anxiety, and ADHD patients. Narcolepsy patients are rare (1 in 2,000 people) and actively searching for specialists who understand their condition. We aggregate that demand across entire states and match patients to providers with the right credentials.

2. Expansion without risk. Want to add narcolepsy as a service line without spending months building a reputation in sleep medicine circles? Want to take patients in a new state where you just got licensed? Our platform gives you instant access to qualified patient flow in that market — no need to start your marketing from scratch.

Think of it as a business development channel that scales with your capacity. See 5 narcolepsy patients a month or 25 — you only pay for the ones you actually treat.

Compliance and Documentation: How to Prescribe Stimulants Safely (and Keep Your License)

Treating narcolepsy via telehealth with controlled substances requires airtight documentation and regulatory compliance. Here’s your checklist:

Federal Requirements (DEA and Ryan Haight Act)

• Valid DEA registration: You must hold an active DEA registration in the state where the patient is located at the time of the telemedicine encounter. If you’re treating patients in California, New York, and Texas, you need DEA registration in all three states.

• Practitioner-patient relationship: Federal law requires a ‘legitimate medical purpose’ and a valid practitioner-patient relationship. This is established through a proper evaluation (audio-visual telehealth visit qualifies under current rules).

• Currently (through 2025): The DEA’s COVID-era flexibilities allow you to prescribe Schedule II–V controlled substances via telehealth without an initial in-person exam. This was extended through at least December 31, 2025.

• After 2025 (potential change): The DEA may require an in-person exam within 30 days of initiating Schedule II prescriptions via telehealth, or they may make the current flexibilities permanent. We’re monitoring this closely and will help providers transition to whatever new requirements emerge.

State Requirements

• PDMP checks: Nearly every state requires prescribers to query the prescription drug monitoring program before prescribing controlled substances. Some states mandate it at every prescription (New York, Kentucky), others require it periodically (e.g., every 3 months for stable patients). Check your state’s rules and document every PDMP query in your notes.

• Informed consent: Many states require written informed consent before prescribing controlled substances via telehealth, covering risks of the medication, alternatives, and your telehealth policies.

• Audio-visual requirement: Virtually all states require video visits for prescribing controlled substances. Audio-only phone calls do not meet the standard of care. (California is an exception that allows audio-only for some services, but controlled substance prescribing is generally excluded.)

• State-specific limits: Watch for Florida’s telehealth ban on Schedule II for non-psychiatric conditions, Texas NP restrictions on Schedule II outpatient prescribing, Pennsylvania’s 30-day NP limit on Schedule II, etc. (See state table below.)

Clinical Documentation Best Practices

Your chart notes should include:

• Diagnosis confirmation: Document review of sleep study results (polysomnogram, MSLT with specific findings like sleep latency <8 minutes, ≥2 SOREMPs for narcolepsy diagnosis). If the patient doesn’t have documentation, note your referral to sleep specialist for testing.

• Symptom assessment: Epworth Sleepiness Scale score, frequency of sleep attacks, presence of cataplexy, impact on daily function (work, school, driving safety).

• Risk assessment: Screen for contraindications to stimulants (uncontrolled hypertension, history of cardiac arrhythmia, active substance use disorder). Document any psychiatric comorbidities (depression, anxiety) and how you’re addressing them.

• PDMP review: Note date and time you checked the state PDMP, and summarize findings (e.g., ‘PDMP reviewed — no other controlled substance prescriptions in past 6 months’ or ‘Patient currently on alprazolam 0.5mg from Dr. Smith for anxiety — discussed interaction risk and coordinated care’).

• Treatment plan and informed consent: Document discussion of medication options, side effects, monitoring plan (blood pressure checks, weight monitoring, follow-up schedule), and patient agreement to treatment.

• Follow-up notes: At each visit, update symptom severity, side effects, blood pressure/heart rate (ask patient to use home monitor or report last PCP reading), medication adherence, and any dose adjustments. Renew PDMP query each time you prescribe.

This level of documentation takes 5–10 minutes per visit if you use templates. It protects you from regulatory scrutiny and also provides excellent clinical continuity.

State-by-State Prescribing Authority: Quick Reference Table

Here’s a summary of narcolepsy prescribing rules for psychiatrists and PMHNPs in key states:

Note: This table reflects laws as of February 2026. Regulatory landscapes can change — always verify current requirements with your state medical/nursing board and the DEA.

FAQ: Telehealth Narcolepsy Prescribing

Q: Do I need to see a narcolepsy patient in person before prescribing stimulants via telehealth?

A: Currently (through end of 2025), federal DEA rules allow you to prescribe Schedule II–V controlled substances via telehealth without an initial in-person exam. After 2025, this may change — the DEA is considering either permanent flexibilities or a requirement for in-person evaluation within 30 days of initiating controlled substances. Additionally, a few states (like Florida for non-psychiatric conditions) require in-person exams regardless of federal rules. Check both federal and state requirements.

Q: Can a PMHNP in Texas manage narcolepsy patients?

A: A Texas PMHNP can manage narcolepsy patients clinically but cannot independently prescribe Schedule II stimulants (Adderall, Ritalin) for outpatient use — Texas law restricts NP Schedule II prescribing to hospital inpatients and hospice patients. You can prescribe modafinil or armodafinil (Schedule IV), but for stimulants, your collaborating physician must write those prescriptions. This makes fully independent narcolepsy practice difficult for Texas NPs.

Q: How often do I need to see narcolepsy patients for medication management?

A: During initial titration (first 2–3 months), monthly visits are typical to adjust doses and monitor side effects. Once stable, most patients can be seen every 3 months. However, federal law prohibits refills on Schedule II prescriptions, so if you’re prescribing amphetamines or methylphenidate, you must write a new prescription every 30 days (either monthly visits or post-dated prescriptions in some states). Modafinil (Schedule IV) can have refills, allowing quarterly visits.

Q: What if my narcolepsy patient doesn’t have a sleep study confirming the diagnosis?

A: You should refer them to a sleep specialist for polysomnography (overnight sleep study) and multiple sleep latency testing (MSLT). Narcolepsy diagnosis requires objective confirmation — clinical symptoms alone aren’t sufficient. Starting stimulant therapy without documented diagnosis exposes you to liability and potential DEA scrutiny. Many tele-psychiatrists will provide a referral and manage other psychiatric comorbidities (depression, anxiety) while waiting for the sleep study results, then initiate narcolepsy medication once diagnosis is confirmed.

Q: How do I handle prior authorizations for narcolepsy medications?

A: Prior authorizations are common for modafinil, armodafinil, and newer agents like Sunosi or Wakix. Insurers typically want documentation of confirmed narcolepsy diagnosis (copy of sleep study results), diagnostic codes (ICD-10 G47.41x), and sometimes proof of failed alternatives or contraindications. This paperwork takes 20–40 minutes per patient. If you’re on a platform like Klarity, our administrative team handles PA submissions — you provide clinical documentation, we manage the insurance back-and-forth.

Q: Can I treat narcolepsy patients across multiple states via telehealth?

A: Yes, but you must be licensed in each state where your patients are located at the time of the telehealth visit. Interstate compacts (like NLC for RN/LPN or PSYPACT for psychologists) do not cover physician or NP prescribing. You need full state licensure and DEA registration for each state. Many tele-psychiatrists and PMHNPs hold 3–5 state licenses to expand their patient base. The Interstate Medical Licensure Compact (IMLC) for physicians and enhanced Nurse Licensure Compact (eNLC) states can streamline the process but don’t eliminate licensing requirements.

Q: What’s the billing/reimbursement for narcolepsy medication management?

A: Initial evaluations typically bill as 99204 or 99205 (new patient visit), reimbursing $200–$280 from private insurance, $165–$210 from Medicare. Follow-up medication checks are 99213 or 99214 (established patient), reimbursing $110–$160 (private) or $80–$130 (Medicare). Telehealth parity laws in most states ensure equal reimbursement to in-

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,person%20doctor%27s%20visit%20for%20the
• https://natlawreview.com/article/new-florida-law-allows-telemedicine-prescribing-controlled-substances#:~:text=controlled%20substances%20via%20telemedicine%2C%20with,more%20on
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,drugs%2C%20such%20as
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,require%20a%20physician%20name%3B
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%E2%80%99s%202023%20state%20budget%2C,practice%20without%20a%20collaborative%20relationship
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=Please%20note%2C%20the%20law%20requires,certify%20104%20NPs%20until%202026
• https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation#:~:text=1.%20in%20a%20hospital%20facility,has%20elected%20to%20receive%20hospice
• https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All#:~:text=match%20at%20L1566%20limit%20the,455
• https://www.pacodeandbulletin.gov/Display/pacode?file=%2Fsecure%2Fpacode%2Fdata%2F049%2Fchapter21%2Fs21.284.html#:~:text=,may%20not%20delegate%20prescriptive%20authority